← All trials
NCT06192160
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Oct 15, 2024
- Primary completion
- Jun 10, 2025
- Completion date
- Apr 14, 2026
- First posted
- Jan 5, 2024
- Last posted
- Aug 19, 2024
- Enrollment
- 315
- Arms / groups
- 6 / —
- Source
- AACT · ctgov ingestion
Sponsors
- National Institute of Allergy and Infectious Diseases (NIAID)Lead sponsor
- Vanderbilt UniversityOfficial
- TB AllianceCollaborator
- University of California, BerkeleyOfficial
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.